Global Cardiovascular Drugs Market 2012-2016

Global Cardiovascular Drugs Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio’s analysts forecast the Global Cardiovascular Drugs market to decline at a CAGR of 10.47 percent over the period 2012-2016. One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities. However, the increase in healthcare expenditure could be one of the factors that will contribute to the growth of this market.

TechNavio’s report, the Global Cardiovascular Drugs Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Cardiovascular Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi.

The other vendors mentioned in the report are Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline plc, Solvay SA, Takeda Pharmaceutical Co. Ltd., and The Medicines Co.

Key questions answered in this report:
What will the market size be in 2016 and at what rate will it grow?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by these key vendors?
What are the strengths and weaknesses of these key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.

1. Executive Summary

2. Introduction

3. Market Coverage


Market Overview

Product Offerings

4. Market Landscape

4.1. Global Cardiovascular Drugs Market

Market Size and Forecast

4.2. Key Product Segmentation

4.3. Five Force Analysis

5. Global Anti-hypertensive Drugs Market

Market Overview

Market Size and Forecast

6. Best Selling Anti-hypertensive Drugs

6.1. Diovan/Co-Diovan

Market Overview

Market Size and Forecast

6.2. Blopress

Market Overview

Market Size and Forecast

6.3. Benicar/Benicar HCT

Market Overview

Market Size and Forecast

6.4. Micardis/Micardis HCT

Market Overview

Market Size and Forecast

6.5. Aprovel/CoAprovel (Avapro/Avalide)

Market Overview

Market Size and Forecast

6.6. Tekturna/Rasilez

Market Overview

Market Size and Forecast

6.7. Edarbi

Market Overview

6.8. Cozaar/Hyzaar

Market Overview

Market Size and Forecast

6.9. Norvasc

Market Overview

Market Size and Forecast

6.10. Exforge/Exforge HCT

Market Overview

Market Size and Forecast

6.11. Coversyl

Market Overview

Market Size and Forecast

6.12. Seloken/Toprol-XL

Market Overview

Market Size and Forecast

7. Global Anti-dyslipidemics Drugs Market

Market Overview

Market Size and Forecast

8. Best Selling Anti-dyslipidemic Drugs

8.1. Lipitor

Market Overview

Market Size and Forecast

8.2. Crestor

Market Overview

Market Size and Forecast

8.3. Niaspan

Market Overview

Market Size and Forecast

8.4. TriCor/Trilipix

Market Overview

Market Size and Forecast

8.5. Zetia/Vytorin

Market Overview

Market Size and Forecast

8.6. Tredaptive

Market Overview

9. Global Anti-thrombotics Drugs Market

Market Overview

Market Size and Forecast

10. Best Selling Anti-thrombotic Drugs

10.1. Plavix

Market Overview

Market Size and Forecast

10.2. Lovenox

Market Overview

Market Size and Forecast

10.3. Pradaxa

Market Overview

Market Size and Forecast

10.4. Xarelto

Market Overview

10.5. Brilique/Brilinta

Market Overview

10.6. Eliquis

Market Overview

11. Drug Pipeline Analysis

12. Geographical Segmentation

13. Key Leading Countries


USA

Germany

Japan

14. Rate of Incidence and Prevalence

Dyslipidemia

Hypertension

Hypercholesterolemia

Stroke

15. Vendor Landscape

16. Buying Criteria

17. Market Challenges

18. Market Growth Drivers

19. Drivers and their Impact

20. Impact of Drivers and Challenges

21. Market Trends

22. Key Vendor Analysis


22.1. Pfizer Inc.

22.1.1. Business Overview

22.1.2. Business Segmentation

22.1.3. Key Information

22.1.4. SWOT Analysis

22.2. Bristol-Myers Squibb Co.

22.2.1. Business Overview

22.2.2. Business Segmentation

22.2.3. Key Information

22.2.4. SWOT Analysis

22.3. AstraZeneca plc

22.3.1. Business Overview

22.3.2. Business Segmentation

22.3.3. Key Information

22.3.4. SWOT Analysis

22.4. Novartis AG

22.4.1. Business Overview

22.4.2. Business Segmentation

22.4.3. Key Information

22.4.4. SWOT Analysis

22.5. Merck & Co. Inc.

22.5.1. Business Overview

22.5.2. Business Segmentation

22.5.3. Key Information

22.5.4. SWOT Analysis

22.6. Sanofi S.A.

22.6.1. Business Overview

22.6.2. Business Segmentation

22.6.3. Key Information

22.6.4. SWOT Analysis

23. Other Reports in this Series



List of Exhibits:

Exhibit 1:  Global Cardiovascular Drugs Market 2012-2016 (US$ billion)

Exhibit 2:  Cardiovascular Drugs by Category Segmentation

Exhibit 3:  Global Cardiovascular Drugs Market by Category Segmentation 2012 (percent)

Exhibit 4:  Global Cardiovascular Drugs Market by Category Segmentation 2012-2016 (US$ million)

Exhibit 5:  Global Cardiovascular Drugs Market by Category Segmentation 2012-2016 (in percent)

Exhibit 6:  Global Anti-hypertensive Market 2012-2016 (US$ million)

Exhibit 7:  Global Sales of Diovan/Co-Diovan 2012-2016 (US$ billion )

Exhibit 8: Global Sales of Blopress/Ecard (Atacand/Atacand Plus) 2012-2016 (US$ billion)

Exhibit 9: Global Sales of Benicar/Benicar HCT 2012-2016 (US$ billion)

Exhibit 10: Global Sales of Micardis/Micardis HCT 2012-2016 (US$ billion)

Exhibit 11: Global Sales of Aprovel/CoAprovel (Avapro/Avalide) 2012-2016 (US$ billion)

Exhibit 12: Global Sales of Tekturna/Rasilez 2012-2016 (US$ million)

Exhibit 13:  Global Sales of Cozaar/Hyzaar 2012-2016 (US$ million)

Exhibit 14:  Global Sales of Norvasc 2012-2016 (US$ billion)

Exhibit 15:  Global Sales of Exforge/Exforge HCT 2012-2016 (US$ billion)

Exhibit 16:  Global Sales of Coversyl 2012-2016 (US$ million)

Exhibit 17:  Global Sales of Seloken/Toprol-XL 2012-2016 (US$ million)

Exhibit 18:  Global Anti-dyslipidemic Market 2012-2016 (US$ million)

Exhibit 19:  Global Sales of Lipitor 2012-2016 (US$ billion)

Exhibit 20:  Global Sales of Crestor 2012-2016 (US$ billion)

Exhibit 21:  Global Sales of Niaspan 2012-2016 (US$ million)

Exhibit 22:  Global Sales of TriCor/Trilipix 2012-2016 (US$ million)

Exhibit 23:  Global Sales of Zetia 2012-2016 (US$ billion)

Exhibit 24:  Global Sales of Vytorin 2012-2016 (US$ billion)

Exhibit 25:  Global Anti-thrombotic Market 2012-2016 (US$ million)

Exhibit 26:  Global Sales of Plavix 2012-2016(US$ billion)

Exhibit 27:  Global Sales of Lovenox 2012-2016 (US$ billion)

Exhibit 28:  Global Sales of Pradaxa 2012-2016 (US$ million)

Exhibit 29:  Oral HDL-C-raising Pipeline Drugs

Exhibit 30:  Parenteral HDL-C-raising Pipeline Drugs

Exhibit 31:  Severe Hypercholesterolemia Pipeline Drugs

Exhibit 32:  Anti-inflammatory Pipeline Drugs

Exhibit 33:  Heart Failure Pipeline Drugs

Exhibit 34:  Global Cardiovascular Drugs Market by Geographical Segmentation 2012

Exhibit 35:  Prevalence of Hypertension in 2012

Exhibit 36:  Prevalence of Hypercholesterolemia in 2012

Exhibit 37:  Prevalence of Stroke in 2012

Exhibit 38:  Global Cardiovascular Drugs Market by Vendor Segmentation 2012

Exhibit 39:  Global Cardiovascular Drugs Market by Vendor Segmentation 2016

Exhibit 40:  Business Segmentation of Pfizer Inc.

Exhibit 41: Business Segmentation of Bristol-Myers Squibb Co.

Exhibit 42:  Business Segmentation of AstraZeneca plc

Exhibit 43: Business Segmentation of Novartis AG

Exhibit 44:  Business Segmentation of Merck & Co. Inc.

Exhibit 45:  Business Segmentation of Sanofi S.A.



 



Enquiry Before Buy